Message from Our Leaders

2023–2024 was a milestone year for our organization as we continued to deliver credible, objective evidence to help inform decisions about the best use of drugs and health technologies in Canada.

A key highlight was the announcement by the Government of Canada that Canada’s Drug Agency will be built from CADTH’s existing mandate and functions. It reflects the trust we’ve established with partners within the pan-Canadian drugs and devices environment, as well as our expertise in the sector.

Another proud moment was when the organization was named 1 of the National Capital Region's top employers for 2024. The designation recognizes employers that lead their industries in offering exceptional places to work.

Our health systems continue to be shaped by changes in technology as well as pandemic recovery. The 2022–2025 Strategic Plan, Ahead of the Curve: Shaping Future-Ready Health Systems, positions us well to support evidence-informed decisions to help respond to the challenges — and opportunities — ahead.

We are incredibly proud of the reports that the organization has delivered on system-wide issues like emergency department overcrowding, dementia, and emerging technologies as part of our annual Watch List. The evidence presented in these reports helps health system leaders address the challenges of an ever-changing and complex environment. In addition, we’ve made strides in the pharmaceutical space, with new work that’s focused on drugs for rare diseases and a successful first year of the Formulary Management Expert Committee (FMEC) pilot.

This annual report also showcases examples of the many diverse partnerships that have been critical to our success, not only over the last year, but since the start of our journey to deliver on our 2022–2025 Strategic Plan.

Partnership is 1 of the guiding principles that steers everything we do. Much of our work wouldn’t be possible without consultations with and advice from partners. Partnerships with governments; patients; clinicians; First Nations, Inuit, and Métis leaders; and industry will continue to be crucial as we bring Canada’s Drug Agency to life.

A heartfelt thanks to our Board members; expert and advisory committees; and the patients and caregivers, clinicians, Indigenous leaders, and industry representatives who all contribute valuable insight and perspectives to the organization’s work. We appreciate and highly value your ongoing support.

Our employees and executive leadership team are crucial to our success. Without them, we could not have the ambitious agenda and exciting future that we do, now including Canada’s Drug Agency.

We look forward to our continued collaborations, strong partnerships, and opportunities ahead.

Sincerely,